Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07461077

Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer

Background: Morphology-based embryo selection cannot detect aneuploidy, which is common in advanced maternal age and recurrent pregnancy loss. NICS-AI combines non-invasive chromosome screening (NICS) of cell-free DNA from spent blastocyst culture medium with AI integration of developmental day and morphology to improve embryo ranking.

Methods: This multicenter, single-blind, parallel randomized controlled trial will include 520 participants. Participants undergoing conventional IVF will be eligible if they meet either (i) female age 35-43 years or (ii) recurrent miscarriage (≥2 losses <28 gestational weeks, including biochemical pregnancy with serum hCG >25 IU/L). They must consent to blastocyst culture/vitrification and frozen-thawed single blastocyst transfer (SBT), and have ≥2 Day-5/Day-6, 2PN-derived blastocysts with morphology grade ≥4BC/4CB at randomization. Key exclusions include any ICSI-based fertilization or PGT-related procedures, known genetic disease meeting PGT indications, donor oocytes, untreated uterine anomalies/hydrosalpinx, or contraindications to pregnancy/ART.

Randomization/interventions: Participants will be randomized 1:1 to NICS-AI-guided selection or morphology-based selection. In the NICS-AI arm, culture-medium DNA is tested and an AI-derived composite implantation score ranks embryos; controls use morphology alone (tie-break by cryopreservation order).

Outcomes/analysis: The primary endpoint is live birth after the first SBT (delivery with ≥1 live-born infant per transfer cycle, per randomized participant). Secondary endpoints include first clinical pregnancy, early miscarriage (<12 weeks, excluding biochemical pregnancy), ongoing pregnancy to 12 weeks, and cumulative pregnancy/live birth outcomes within 1 year (≤3 SBTs from one retrieval). Safety includes fetal malformations and neonatal outcomes through 1 year postpartum.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Advanced Age Embryo Quality Genital Diseases Infertility Infertility (IVF Patients) Recurrent Pregnancy Loss(RPL) Sequence Analysis Urogenital Diseases

Age range

20 year–43 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Guangzhou, Guangdong, 510120, China

Location contact

Ping Yuan, Doctor

CONTACT

[email protected]

+8613751885713

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Conventional IVF insemination;
  • Meeting either of the following:
  • Advanced maternal age: female age 35-43 years;
  • Recurrent miscarriage: ≥2 spontaneous pregnancy losses (<28 gestational weeks), including biochemical pregnancy (hCG >25 IU/L) ;
  • Willingness to culture all Day 3 embryos to the blastocyst stage in the fresh cycle, or to culture ≥6 embryos (with at least one embryo ≥7 cells), and to cryopreserve all blastocysts as single-blastocyst vitrification;
  • Willingness to undergo frozen-thawed single-blastocyst transfer;
  • At least two blastocysts formed on Day 5/Day 6 from 2PN fertilization, with morphological grading ≥4BC/4CB;
  • Provision of written informed consent.

Exclusion criteria

  • Any use of intracytoplasmic sperm injection-based fertilization, including but not limited to ICSI, TESA, and PGT-related cycles;
  • Known monogenic disorders or chromosomal abnormalities at enrollment;
  • Patients who use donated eggs to achieve pregnancy;
  • Definite conditions affecting uterine cavity anatomy or endometrial receptivity, such as untreated uterine malformations (e.g., septate uterus, unicornuate uterus, didelphys uterus) or untreated hydrosalpinx;
  • Contraindications to pregnancy or to assisted reproductive technology;
  • Any other condition deemed by the investigators to make the participant unsuitable for this study.

Treatment and study plan

NICS-AI

Other
  • Collection of spent blastocyst culture medium and embryo cryopreservation: after thorough removal of granulosa cells from the zona pellucida, Day-4 embryos are washed and the medium is refreshed. When the embryo reaches an expanded stage-4 blastocyst (about 180 um), pre-freeze collapse is performed and the culture medium is collected. Samples are stored at -20 ℃ pending testing; blastocysts are vitrified.
  • Testing and scoring: samples undergo whole-genome amplification, library preparation, and sequencing. An AI-assisted model integrates sequencing results (including CNV resolution, mosaicism, euploidy/sex chromosome status, number of abnormal chromosomes), morphology grade, and day of blastulation to generate a composite implantation potential score (reported as <10 or 10-66).
  • Frozen-thawed single blastocyst transfer: embryos are prioritized for transfer from highest to lowest composite score. If scores are identical, embryos are prioritized by cryopreservation order.

Morphology group

Other
  • When the embryo reaches an expanded stage-4 blastocyst (about 180 um), pre-freeze collapse is performed and the culture medium is collected. Samples are stored at -20 C pending testing; blastocysts are vitrified.
  • Single-blastocyst transfer in frozen-thawed cycles, determined solely by the day of blastulation and morphological grading:

i) Day 5 blastocysts are prioritized over Day 6 blastocysts (Day 5 > Day 6); ii) For blastocysts formed on the same day, prioritization follows this order: 6AA > 6BA > 6AB > 5AA > 5BA > 5AB > 4AA > 4BA > 4AB > 6BB > 5BB > 4BB > 6CA > 5CA > 6CB > 5CB > 4CA > 4CB > 6AC > 5AC > 6BC > 5BC > 4AC > 4BC; iii) If both the day of blastulation and the morphological grade are identical, embryos are transferred according to the order of cryopreservation (e.g., based on the cryo-straw identification number).

  • For all enrolled patients, the study-designated (enrolled) blastocysts are prioritized for transfer.

Primary outcomes

  1. Live birth rate of the first frozen embryo transfer

    Time frame: At delivery (following the first frozen embryo transfer)

    live birth: number of deliveries resulting in at least one live-born infant per embryo transfer cycle Live birth rate of the first frozen embryo transfer = (No. of deliveries with live-born infant(s) after the last embryo transfer / No. of randomized patients) × 100%

Secondary outcomes

  1. Clinical pregnancy rate of the first frozen embryo transfer

    Time frame: 4 weeks after the first frozen embryo transfer

    clinical pregnancy: ultrasonographic detection of one or more gestational sacs, including intrauterine pregnancy, ectopic pregnancy, and heterotopic pregnancy。 Clinical pregnancy rate of the first frozen embryo transfer = (No. of patients achieving clinical pregnancy of the first frozen embryo transfer / No. of randomized patients) × 100%

  2. Early miscarriage rate of the first frozen embryo transfer

    Time frame: From clinical pregnancy confirmation to 12 gestational weeks (following the first frozen embryo transfer)

    early miscarriage: spontaneous pregnancy loss before 12 completed gestational weeks, excluding biochemical pregnancy) Early spontaneous miscarriage rate of the first frozen embryo transfer = (No. of patients with early spontaneous miscarriage <12 weeks of the first frozen embryo transfer / No. of patients with clinical pregnancy) × 100%

  3. Ongoing pregnancy rate of the first frozen embryo transfer

    Time frame: At 12 gestational weeks (following the first frozen embryo transfer)

    Ongoing pregnancy rate at 12 gestational weeks after the first frozen embryo transfer, Ongoing pregnancy rate of the first frozen embryo transfer = (No. of participants with an ongoing pregnancy at 12 gestational weeks following the first FET / No. of randomized participants) × 100%

  4. Cumulative clinical pregnancy rate

    Time frame: From the first single-blastocyst transfer; clinical pregnancy assessed at 4 weeks after each transfer; up to three transfers within 12 months after randomization.

    Cumulative clinical pregnancy rate: within a single oocyte-retrieval cycle; up to three single-blastocyst transfers within 1 year after randomization; meeting the definition of clinical pregnancy Cumulative clinical pregnancy rate = (No. of patients achieving clinical pregnancy during the transfer period / No. of randomized patients) × 100%

  5. Cumulative early miscarriage rate

    Time frame: From the first single-blastocyst transfer; follow-up through 12 gestational weeks for each pregnancy achieved (max 3 transfers within 12 months after randomization).

    Cumulative early miscarriage rate: within a single oocyte-retrieval cycle; up to three single-blastocyst transfers within 1 year after randomization; meeting the definition of early miscarriage Cumulative early miscarriage rate = (No. of patients with early spontaneous miscarriage <12 weeks during the transfer period / No. of patients with clinical pregnancy during the transfer period) × 100%

  6. Cumulative ongoing pregnancy rate

    Time frame: From the first single-blastocyst transfer; follow-up through 12 gestational weeks for each pregnancy achieved (max 3 transfers within 12 months after randomization).

    Cumulative ongoing pregnancy rate: within a single oocyte-retrieval cycle; up to three single-blastocyst transfers within 1 year after randomization; ongoing to 12 gestational weeks Cumulative ongoing pregnancy rate = (No. of patients with an ongoing pregnancy during the transfer period / No. of randomized patients) × 100%

  7. Cumulative live birth rate

    Time frame: From the first single-blastocyst transfer; assessed at delivery for pregnancies achieved within 12 months after randomization (max 3 transfers).

    Cumulative live birth rate: within a single oocyte-retrieval cycle; up to three single-blastocyst transfers within 1 year after randomization; meeting the definition of live birth Cumulative live birth rate = (No. of live births delivered during the transfer period / No. of randomized patients) × 100%

Study contacts

Contact information is provided by the study sponsor or research team.

Haijing Zhao

CONTACT

[email protected]

+8615217456163

Ping Yuan, Doctor

CONTACT

[email protected]

+8613751885713

Sponsors and collaborators

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Other

Registry information

Official study title

Clinical Outcomes of Non-invasive Embryo Implantation Potential Assessment Versus Conventional Morphological Selection for Single Blastocyst Transfer Following Conventional IVF: A Multicenter Randomized Controlled Trial

Acronym: NICSAI-SBT-RCT

Important dates

Study start
2026
Primary completion
2030
Study completion
2032
First posted
Mar 10, 2026
Registry last updated
Mar 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.